ClinicalTrials.gg
CompletedNCT01130493Updated Oct 29, 2019Results posted

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066

A Phase 3 interventional study of IPX066 and CLE in Parkinson's Disease, sponsored by Impax Laboratories, LLC. Completed at 24 sites in 4 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2019-10-29.

Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · Amneal Pharmaceuticals, Inc..

Enrollment
7th of 14
110 · median 77
Started
2010
with 1 other
Phase 3
7 of 14
none open now
Registered
8th of 14
by date

Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., this one is the 7th largest by enrollment, is one of 2 that started in 2010, is one of 7 in phase 3, and was the 8th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

This is a study to compare the efficacy of IPX066 and CLE in subjects with advanced Parkinson's disease.

Read the detailed description

This is a randomized, double-blind, double-dummy, 2 treatment, 2-period crossover study followed by an open-label extension study period.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with idiopathic Parkinson's Disease (PD).
  2. At least 30 years old at the time of PD diagnosis.
  3. Currently being treated with carbidopa/levodopa/entacapone (CLE) and on a stable regimen of conventional LD for at least 4 weeks and:

    • Requiring a total daily levodopa (LD) dose of at least 400 mg
    • Having a minimum dosing frequency of four times per day.
    • Individual CD-LD or CLE doses that contain an LD dose which is a multiple of 50 mg.
  4. Able to differentiate "on" state from "off" state.
  5. Have predictable "off" periods.
  6. Amantadine, anticholinergics, selective monoamine oxidase (MAO) type B inhibitors (e.g., selegiline, rasagiline) or dopamine agonists are allowed as long as the doses and regimens have been stable for at least 4 weeks prior to Screening and the therapy is intended to be constant throughout the course of the study.
  7. Agrees to use a medically acceptable method of throughout the study and for 1 month afterward.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with atypical Parkinsonism or any known secondary Parkinsonian syndrome.
  2. Nonresponsive to LD therapy.
  3. Prior functional neurosurgical treatment for PD (e.g., ablation or deep brain stimulation) or if such procedures are anticipated during study participation.
  4. Received within 4 weeks of Screening or planning to take during participation in the clinical study: any controlled-release LD product, tolcapone, apomorphine, nonselective MAO inhibitors, or antipsychotics including neuroleptic agents for the purpose of treating psychosis or bipolar disorder.
  5. Allergy or to CD, LD, entacapone, riboflavin, Yellow Dye #5 (tartrazine), citrus fruit or grape juice.
  6. History of or currently active psychosis.
  7. Active or prior medical conditions such as peptic ulcers or prior surgical (e.g., bowel) procedures that would interfere with LD absorption.
  8. Active or history of narrow-angle glaucoma.
  9. History of malignant melanoma or a suspicious undiagnosed skin lesion.
  10. History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias, upper gastrointestinal hemorrhage, or neuroleptic malignant syndrome or nontraumatic rhabdomyolysis.
  11. Received any medications during the 4 weeks prior to Screening.
  12. Unable to swallow large pills (e.g., large vitamin pills).
  13. Pregnant or breastfeeding.
  14. Subjects who are unable to complete a symptom diary.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Other
    IPX066-CLE-OLE

    Dose conversion from CLE to IPX066, IPX066 (Part 1 Period 1), Open-label IPX066, CLE (Part 1 Period 2), OLE (Part 2)

    Drug: IPX066 · Drug: CLE

  • Other
    CLE-IPX066-OLE

    Dose conversion from CLE to IPX066, CLE (Part 1 Period 1), Open-label IPX066, IPX066 (Part 1 Period 2), OLE (Part 2)

    Drug: IPX066 · Drug: CLE

Interventions

  • DrugIPX066

    experimental product

    Also known as: extended-release carbidopa-levodopa

  • DrugCLE

    Drug pages: Carbidopa · Levodopa · Entacapone

    active comparator

    Also known as: carbidopa/levodopa/entacapone

06

What researchers measure

Primary outcomes

  1. Percentage of "OFF" Time During Waking Hours

    Using a Parkinson's disease diary, subjects recorded a state of "asleep", "OFF", "ON without dyskinesia," "ON with non-troublesome dyskinesia," or "ON with troublesome dyskinesia" every 30 minutes over a 24-hour day for the last 3 days of each double-blind crossover treatment period. Mean percentage of "OFF" Time During Waking Hours was calculated. "Off" Time is Time when medication has worn off and is no longer providing benefit with regard to mobility, slowness, and stiffness.

    Time frame: 3 days of data immediately prior to the end of each 2 week treatment period

Secondary outcomes

  1. Total "OFF" Time During Waking Hours

    Using a Parkinson's disease diary, subjects recorded a state of "asleep", "OFF", "ON without dyskinesia," "ON with non-troublesome dyskinesia," or "ON with troublesome dyskinesia" every 30 minutes over a 24-hour day for the last 3 days of each double-blind crossover treatment period. Mean Total "Off" Time During Waking Hours was calculated. "Off" Time is Time when medication has worn off and is no longer providing benefit with regard to mobility, slowness, and stiffness.

    Time frame: 3 days of data immediately prior to the end of each 2 week treatment period

  2. Total "On" With No Troublesome Dyskinesia

    Using a Parkinson's disease diary, subjects recorded a state of "asleep", "OFF", "ON without dyskinesia," "ON with non-troublesome dyskinesia," or "ON with troublesome dyskinesia" every 30 minutes over a 24-hour day for the last 3 days of each double-blind crossover treatment period. Mean Total "On" with No Troublesome Dyskinesia was calculated. "On" Time is when medication is providing benefit with regard to mobility, slowness, and stiffness.

    Time frame: 3 days of data immediately prior to the end of each 2 week treatment period

  3. UPDRS Part II Plus Part III

    Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) and Part III (Motor Examination). Part II consists of 14 questions, each ranges from 0 (Normal/None) - 4 (Worst) with a total score of 0 - 72. Part III consists of 27 questions, each ranges from 0 (Normal/None) - 4 (Worst) with a total score of 0 - 108. The UPDRS Part II Plus Part III scores ranged from 0 (no problems with daily living or mobility) to 180 (severe problems with daily living and mobility.

    Time frame: End of each double-blind treatment period.

  4. Subject Preference

    Subjects who completed both treatments were asked to indicate a preference for Treatment Period 1 or Treatment Period 2 or no preference. Preferences for a particular treatment period were mapped to the associated treatment and reported.

    Time frame: End of Study (week 11)

07

Results

Posted Sep 13, 2017

Participant flow

Date first patient enrolled: March 22, 2011 Date last patient completed: January 12, 2012

Open-label Dose Conversion to IPX066
Participant flow — Open-label Dose Conversion to IPX066
MilestoneIPX066 ConversionIPX066-Open-label IPX066 Washout-CLE-OLECLE-Open Label IPX066 Washout-IPX066-OLE
Started11000
Completed9100
Not completed1900
Withdrew: Adverse event100
Withdrew: Protocol violation300
Withdrew: Lack of efficacy700
Withdrew: Withdrawal by subject700
Withdrew: Diary imcomplete100
Part 1: Double-blind Treatment Period 1
Participant flow — Part 1: Double-blind Treatment Period 1
MilestoneIPX066 ConversionIPX066-Open-label IPX066 Washout-CLE-OLECLE-Open Label IPX066 Washout-IPX066-OLE
Started04843
Completed04643
Not completed020
Withdrew: Protocol violation010
Withdrew: Lack of efficacy010
Part 1: Open-Label IPX066 Washout
Participant flow — Part 1: Open-Label IPX066 Washout
MilestoneIPX066 ConversionIPX066-Open-label IPX066 Washout-CLE-OLECLE-Open Label IPX066 Washout-IPX066-OLE
Started04643
Completed04541
Not completed012
Withdrew: Lack of efficacy010
Withdrew: Adverse event001
Withdrew: Withdrawal by subject001
Part 1: Double-blind Treatment Period 2
Participant flow — Part 1: Double-blind Treatment Period 2
MilestoneIPX066 ConversionIPX066-Open-label IPX066 Washout-CLE-OLECLE-Open Label IPX066 Washout-IPX066-OLE
Started04541
Completed04539
Not completed002
Withdrew: Withdrawal by subject001
Withdrew: Noncompliance001
Part 2: OLE
Participant flow — Part 2: OLE
MilestoneIPX066 ConversionIPX066-Open-label IPX066 Washout-CLE-OLECLE-Open Label IPX066 Washout-IPX066-OLE
Started03935
Completed03630
Not completed035
Withdrew: Adverse event021
Withdrew: Withdrawal by subject014

Outcome measures

PrimaryPercentage of "OFF" Time During Waking Hours

Using a Parkinson's disease diary, subjects recorded a state of "asleep", "OFF", "ON without dyskinesia," "ON with non-troublesome dyskinesia," or "ON with troublesome dyskinesia" every 30 minutes over a 24-hour day for the last 3 days of each double-blind crossover treatment period. Mean percentage of "OFF" Time During Waking Hours was calculated. "Off" Time is Time when medication has worn off and is no longer providing benefit with regard to mobility, slowness, and stiffness.

Time frame:
3 days of data immediately prior to the end of each 2 week treatment period
Reported as:
Mean · Percent
Percentage of "OFF" Time During Waking Hours
PercentIPX066CLE (Active Comparator)
Percentage of "OFF" Time During Waking Hours23.98 ± 16.24232.48 ± 21.917
SecondaryTotal "OFF" Time During Waking Hours

Using a Parkinson's disease diary, subjects recorded a state of "asleep", "OFF", "ON without dyskinesia," "ON with non-troublesome dyskinesia," or "ON with troublesome dyskinesia" every 30 minutes over a 24-hour day for the last 3 days of each double-blind crossover treatment period. Mean Total "Off" Time During Waking Hours was calculated. "Off" Time is Time when medication has worn off and is no longer providing benefit with regard to mobility, slowness, and stiffness.

Time frame:
3 days of data immediately prior to the end of each 2 week treatment period
Reported as:
Mean · hours
Total "OFF" Time During Waking Hours
hoursIPX066CLE (Active Comparator)
Total "OFF" Time During Waking Hours3.82 ± 2.5585.22 ± 3.672
SecondaryTotal "On" With No Troublesome Dyskinesia

Using a Parkinson's disease diary, subjects recorded a state of "asleep", "OFF", "ON without dyskinesia," "ON with non-troublesome dyskinesia," or "ON with troublesome dyskinesia" every 30 minutes over a 24-hour day for the last 3 days of each double-blind crossover treatment period. Mean Total "On" with No Troublesome Dyskinesia was calculated. "On" Time is when medication is providing benefit with regard to mobility, slowness, and stiffness.

Time frame:
3 days of data immediately prior to the end of each 2 week treatment period
Reported as:
Mean · hours
Total "On" With No Troublesome Dyskinesia
hoursIPX066CLE (Active Comparator)
Total "On" With No Troublesome Dyskinesia11.36 ± 3.2599.98 ± 3.764
SecondaryUPDRS Part II Plus Part III

Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) and Part III (Motor Examination). Part II consists of 14 questions, each ranges from 0 (Normal/None) - 4 (Worst) with a total score of 0 - 72. Part III consists of 27 questions, each ranges from 0 (Normal/None) - 4 (Worst) with a total score of 0 - 108. The UPDRS Part II Plus Part III scores ranged from 0 (no problems with daily living or mobility) to 180 (severe problems with daily living and mobility.

Time frame:
End of each double-blind treatment period.
Reported as:
Mean · Scores on a scale
UPDRS Part II Plus Part III
Scores on a scaleIPX066CLE (Active Comparator)
UPDRS Part II Plus Part III29.3 ± 15.0231.7 ± 14.89
SecondarySubject Preference

Subjects who completed both treatments were asked to indicate a preference for Treatment Period 1 or Treatment Period 2 or no preference. Preferences for a particular treatment period were mapped to the associated treatment and reported.

Time frame:
End of Study (week 11)
Reported as:
Count of participants · Participants
Subject Preference
ParticipantsNumber of Participants Who Preferred IPX066Number of Participants Who Preferred CLENumber of Participants Who Had no Preference
Subject Preference442317

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Conversion—2/91 (2.2%)14/91 (15.4%)
IPX066—1/89 (1.1%)13/89 (14.6%)
CLE (Active Comparator)—0/88 (0%)2/88 (2.3%)
Washout—1/89 (1.1%)1/89 (1.1%)
Most frequent serious events
Most frequent serious events
EventDose ConversionIPX066CLE (Active Comparator)Washout
DehydrationMetabolism and nutrition disorders0/910/890/881/89
SciaticaNervous system disorders0/911/890/880/89
Atrial FibrillationCardiac disorders1/910/890/880/89
Gastrointestinal ToxicityGastrointestinal disorders1/910/890/880/89
ConstipationGastrointestinal disorders1/910/890/880/89
HypercalemiaMetabolism and nutrition disorders1/910/890/880/89
Most frequent other events
Most frequent other events
EventDose ConversionIPX066CLE (Active Comparator)Washout
NauseaGastrointestinal disorders6/911/890/880/89
DyskinesiaNervous system disorders1/914/890/881/89
InsomniaPsychiatric disorders1/913/890/880/89
Confusional StatePsychiatric disorders0/913/890/880/89
FallInjury, poisoning and procedural complications2/911/892/880/89
Upper Respiratory InfectionInfections and infestations2/910/890/880/89
VomitingGastrointestinal disorders2/911/890/880/89

Baseline characteristics

Participants who completed the Dose Conversion period and were randomized into the double-blind crossover portion of the study.

Age, Categorical
Age, Categorical(Participants)All Study Participants
<=18 years0
Between 18 and 65 years50
>=65 years41
Age, Continuous
Age, Continuous(years)All Study Participants
Mean64.1 ± 9.34
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female23
Male68
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Study Participants
Hispanic or Latino8
Not Hispanic or Latino79
Unknown or Not Reported4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Study Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White89
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(participants)All Study Participants
United States44
Italy26
Germany21
08

Study locations

24 sites
  • Margolin Brain Institute
    Fresno, California 93720, United States
  • The Parkinson's Institute in Sunnyvale
    Sunnyvale, California 94085, United States
  • UM Movement Disorders Center
    Miami, Florida 33136, United States
  • Charlotte Neurological Services
    Port Charlotte, Florida 33980, United States
  • USF Parkinson's and Movement Disorders Center
    Tampa, Florida 33606, United States
  • Quest Research Institute
    Bingham Farms, Michigan 48025, United States
  • University Health Systems
    Las Vegas, Nevada 89102, United States
  • Parkinson's Disease and Movement Disorders Center of Long Island
    Commack, New York 11725, United States
  • Kingston Neurological Associates
    Kingston, New York 12401, United States
  • University Neurology, Inc
    Cincinnati, Ohio 45219, United States
  • Sentara Neurological Associates
    Virginia Beach, Virginia 23456, United States
  • Booth Gardner Parkinson's Care Center
    Kirkland, Washington 98034, United States
  • Hôpital Gabriel Montpied-Service de Neurologie A-
    Clermont-Ferrand Cedex 1, 63003, France
  • Service de neurologie-Hôpital de la Timone-
    Marseille, 13385, France
  • Praxis für Neurologie, Psychiatrie und Psychotherapie Achim
    Achim, 28832, Germany
  • Praxis Dres. Bitter/Schumann
    Bochum, 44805, Germany
  • Klinikum rechts der Isar der Technischen Universität München
    München, 81675, Germany
  • Klinik für Neurologie, Stadtroda
    Stadtroda, 07646, Germany
  • RKU, Neurologische Klinik der Universität Ulm
    Ulm, 89081, Germany
  • Casa di Cura Villa Margherita
    Arcugnano, 36057, Italy
  • San Raffaele Cassino, San Raffaele Cassino,
    Cassino, 03043, Italy
  • Dipartimento di Oncologia e Neuroscienze, Università G. D'Annunzio
    Chieti, 66013, Italy
  • Ospedale della Misericordia
    Grosseto, 58100, Italy
  • IRCCS San Raffaele Pisana
    Roma, 163, Italy
09

References and documents

Publications

  • Morgan JC, Dhall R, Rubens R, Khanna S, Gupta S. Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations. Parkinsons Dis. 2018 Oct 22;2018:9763057. doi: 10.1155/2018/9763057. eCollection 2018. PubMed 30425824 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2017, 5 years 8 months after primary completion. A results delay was requested in Sep 2013.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2010
First posted
May 26, 2010
Start
May 2010
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Results delay requested
Sep 27, 2013
Results first posted
Sep 13, 2017
Last update
Oct 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01130493
Responsible party
Sponsor
First posted
May 26, 2010
Start date
May 2010
Primary completion
Jan 2012
Completion
Jan 2012
Results posted
Sep 13, 2017
Last update
Oct 29, 2019

Study contacts

Impax Study Director
study director · Impax Laboratories, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion